INS and Alzheimer disease: In 2012, Craft et al. ran a longer pilot clinical trial to investigate the effect of intranasal insulin on cognition, function, cerebral glucose metabolism, and CSF biomarkers in 104 adults with either AMCI (n = 64) or mild to moderate AD (n = 40) over the span of 4 months [80].